| ln Vitro |
MO-2097 (10-30 μM, 24-48 h) inhibited the migration of DLD-1 and HCT116 cells[1]. MO-2097 (10-50 μM, 1-6 h) inhibited the RAF-1-driven RAF/MEK/ERK signaling pathway in DLD-1 and HCT116 cells[1]. MO-2097 (10-30 μM, 5-9 h) inhibited the invasiveness of colorectal cancer cells (DLD-1 and HCT116 cells) in 3D tumor spheroids[1]. MO-2097 (30-100 μM, 4 h) inhibited angiogenesis by suppressing tubular formation in HUVEC cells[1]. MO-2097 (25-500 μM, 24 h) has low toxicity, can directly bind to hnRNPA2B1, and inhibit the expression of HIF-1α in HeLa CCL2 and HCT116 cells [2]. Under hypoxic conditions, MO-2097 (25-50 μM, 24 h) can inhibit the expression levels of HIF-1α target gene mRNAs (HK1, MRP1, SLC1A5, IL-6 and VEGF) in HeLa CCL2 and HCT116 cells [2]. MO-2097 (12.5-50 μM, 24 h) can induce the production of mitochondrial ROS, which in turn leads to apoptosis, manifested as the cleavage of caspase 3 and caspase 9 in HeLa CCL2 cells [2]. MO-2097 (12.5-50 μM, 7-10 days) induced specific anticancer effects in hypoxic regions of 3D cultured spheroid models and 3D cultured human colon cancer organoids [2].
|
|---|---|
| ln Vivo |
MO-2097 (25-50 mg/kg, intraperitoneal injection, every other day for 15 days) induces tumor cell apoptosis by inhibiting HIF-1a expression, thereby reducing tumor growth in a mouse model of xenografted HCT116 cells [1].
|
| Cell Assay |
Cell migration assay [1]
Cell Types: DLD-1 and HCT116 cells Tested Concentrations: 10, 20, 30 μM Incubation Duration: 24, 48 hours Experimental Results: Compared with the control group, the cell migration of DLD-1 cells and HCT116 cells was inhibited by 86.5% and 77.5%, respectively. Western Blot Analysis [1] Cell Types: DLD-1 and HCT116 cells Tested Concentrations: 10, 20, 30, 40, 50 μM Incubation Duration: 1, 2, 4, 6 hours Experimental Results: In cells treated with cyclohexylimide (CHX) alone, RAF-1 levels gradually decreased. It inhibited RAF-1 accumulation without affecting proteasome degradation. It reduced the phosphorylation levels of MEK and ERK. It reduced the levels of transcription factors Snail, Slug, and ZEB1. Immunofluorescence [2] Cell Types: HeLa CCL2 cells Tested Concentrations: 12.5, 25, 50 μM Incubation Duration: 24 hours Experimental Results: Under hypoxic conditions, the content of HIF-1α protein in the cell nucleus was reduced in a dose-dependent manner. Mitochondrial ROS production was induced.
|
| Animal Protocol |
Animal/Disease Models:Male Balb/C nude mice (6 weeks old) xenografted HCT116 cells (2 × 10⁵ cells/mouse) [1]
Doses: 25, 50 mg/kg Route of Administration: Intraperitoneal injection, every other day for 15 days Experimental Results: Tumor volume decreased by approximately 49%, without causing significant weight loss. HIF-1α expression decreased. Cleaved caspase 3 expression increased. |
| References |
| CAS # |
2744300-63-6
|
|---|---|
| Appearance |
Typically exists as solids at room temperature
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
